Astec lifesciences Limited has completed the allotment of 577 equity shares under its Employee Stock Option Plan (ESOP) 2012, as approved by the company's Nomination and Remuneration Committee on 24th February, 2026. The allotment represents the exercise of stock options granted to employees under the company's incentive program.

ESOP Exercise Details

The allotment comprised options exercised under two different schemes within the ESOP 2012 framework:

The original Employee Stock Option Plan 2012 was approved by shareholders through a special resolution at an extraordinary general meeting held on 27th March, 2012. The amended version received shareholder approval via special resolution through postal ballot on 26th September, 2021, with results declared on 27th September, 2021.

Share Capital Impact

Following the allotment of 577 equity shares, each with a face value of Rs. 10.00, the company's capital structure has been updated:

The newly allotted shares rank pari passu with existing equity shares and are fully paid up. This allotment reflects the company's ongoing commitment to its employee incentive programs and provides employees with the opportunity to participate in the company's equity growth.

Regulatory Compliance

The allotment was conducted in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed both BSE Limited and National Stock Exchange of India Limited about this corporate action, ensuring full transparency with market regulators and stakeholders.

Astec LifeSciences has announced significant leadership changes alongside improved Q3FY26 financial performance, with the company reporting a 61% reduction in consolidated net loss and 31% revenue growth. The agrochemicals company also disclosed key management transitions including CFO resignation and appointment.

Q3FY26 Financial Performance

The company delivered strong operational improvements across key financial metrics for the quarter ended December 31, 2025:

Leadership Changes and Management Transition

The Board of Directors noted the resignation of Ms. Mugdha Amol Khare as Chief Financial Officer, effective from the close of business hours on March 6, 2026. She is resigning to pursue career opportunities outside the company.

Mr. Deepak Jawaharlal Ochani, a qualified Chartered Accountant and member of ICAI, will take over as CFO from April 1, 2026. He brings extensive expertise in financial management, compliance, governance, and has strong capabilities in financial planning and analysis, budgeting, and working capital management.

Revenue Growth and Segment Performance

Astec LifeSciences achieved consolidated total income of ₹125.5 crore in Q3FY26, representing a 31% increase from ₹95.8 crore in the corresponding quarter of the previous year. The growth was driven by improved performance across both business segments:

EBITDA Turnaround and Exceptional Items

The company achieved positive EBITDA of ₹4.8 crore in Q3FY26, compared to an EBITDA loss of ₹3.8 crore in Q3FY25. According to Chairman N B Godrej, the company delivered strong revenue growth recording 1.3x growth over Q3FY25 driven by higher Enterprise volumes and improved offtake in the Contract Manufacturing segment.

Exceptional items of ₹2.1 crore in Q3FY26 primarily arose from regulatory changes related to four Labour Codes notification by the Government of India, affecting gratuity and long-term compensated absences due to revised wage definitions.

Nine Months Performance Overview

For the nine months period ended December 31, 2025, the company showed consistent improvement: